Skip to content

Effects of irbesartan on the pharmacokinetics and pharmacodynamics of repaglinide

Effects of irbesartan on the pharmacokinetics and pharmacodynamics of repaglinide

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16009697
Enrollment
Unknown
Registered
2016-11-01
Start date
2016-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

two:irbesartan

Sponsors

The Third Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Male or female, healthy participants, aged from 18 to 45 years, BMI 19 to 25 kg/m2; 2. No addiction to alcohol or drugs, non-smokers; 3. Healthy participants confirmed by physical examination, disease history, vital signs, ECG and laboratory tests; with no diseases of heart, liver, kidney, gastrointestinal system, neurological system; with no psychiatric or metabolic disorders; 4. With normal BP, HR, ECG, respiratory rate, liver and kidney function, and blood count; 5. Sign the written informed consent before the study; 6. With sufficient ability to communicate and to fulfill the study.

Exclusion criteria

Exclusion criteria: 1. Allergic to active pharmaceutical ingredients; 2. With gastrointestinal tract diseases; 3. With history of drug abuse within five years; 4. Use of drugs that might cause injury to organs within three months; 5. Use of other drugs within 14 days before the study; 6. Participates in other trials within 3 months; 7. Suffer from severe blood loss within 30 days before the study; 8. With diseases of primary organs; 9. Smokers or alcohol abusers; 10. Addictive to sedative and other drugs; 11. Patients that researchers regard not eligible for inclusion.

Design outcomes

Primary

MeasureTime frame
concentration of repaglinide;concentration of irbesartan;blood sugar;insulin;

Contacts

Public ContactQI PEI

The Third Xiangya Hospital, Central South University

peiqi1028@126.com+86 13170419804

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026